GB Patent

GB2461186A — Sustained release composition for intratympanic delivery of corticosteroid

Assigned to Otonomy Inc · Expires 2009-12-30 · 16y expired

What this patent protects

A formulation for intratympanic administration of corticosteroids across the round window membrane into the cochlea is disclosed, wherein the formulation is an auris-acceptable gel, and the delivery is in a sustained release form. The formulation is preferably a thermoreversible …

USPTO Abstract

A formulation for intratympanic administration of corticosteroids across the round window membrane into the cochlea is disclosed, wherein the formulation is an auris-acceptable gel, and the delivery is in a sustained release form. The formulation is preferably a thermoreversible gel, such as a polyoxyethylene-polyoxypropylene triblock copolymer. The corticosteroid is preferably dexamethasone phosphate or dexamethasone acetate, and may be used in the treatment of Meniere's disease or sensorineural hearing loss.

Drugs covered by this patent

Patent Metadata

Patent number
GB2461186A
Jurisdiction
GB
Classification
—
Expires
2009-12-30
Drug substance claim
No
Drug product claim
No
Assignee
Otonomy Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.